Back to top

Aggressive Growth

Transcept Pharmaceuticals, Inc reported narrower than expected losses last period, but the attention is still centered on the approval its new insomnia medication.

Estimates and shares are rising making this a hot Zacks #1 Rank (Strong Buy).

Company Description

Transcept Pharmaceuticals develops and commercializes proprietary products in the neuroscience field. The most prominent product is Intermezzo, which is awaiting approval from the FDA and treats insomnia patients.

Better than Expected Results

Last quarter, reported on May 16, Transcept reported a loss of $0.14 per share, which was 13 cents narrower than expected. This was the third consecutive earnings surprise.

They currently have $63.3 million left in cash and are averaging about $1.6 million per month in spending. Transcept brought in $3.1 million in revenue for the period from a license fee. That 24-month non-refundable fee has been coming in since August 2009 and will total $25 million when completed.

Investors are patiently awaiting the FDA's decision on Intermezzo's New Drug Application, which should be out on July 14th. Other popular drugs help patients fall asleep, but Intermezzo is will serve those who awake in the middle of the night.

Estimates Pop

After the quarterly report analysts raised both annual and quarterly estimates. The Zacks Consensus Estimate for 2011 is up 40 cents, to $0.89. Next year's jumped 32 cents, to $0.30.

The drop off in 2012 is due to the end of that licensing fee. While there is not the typical year-over-year growth of a typical aggressive growth company, the rapid and sharp upward estimate revisions are enough. Also, earnings should growth from 2012 and beyond.

The Chart

Investors are becoming increasingly confident about the FDA's approval. That has given shares of TSPT momentum as well as growth characteristics.

Transcept Pharmaceuticals, Inc - ticker TSPT>

 
<P ALIGN=

Bill Wilton is the Aggressive Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the Zacks Small Cap Trader service

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%